PUBLICATIONS

Science, shared.

Super-adjuvant nanoparticles for platform cancer vaccination

Cell Reports Medicine · 2025

Nanoparticle encapsulation of synergistic immune agonists enables systemic codelivery to tumor sites and IFNβ-driven antitumor immunity

Cancer Research · 2019

Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers

Nanoscale · 2022

Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma

Molecular Cancer Therapeutics · 2026

© 2026 NanoVax Therapeutics, Inc. All rights reserved.

Our investigational technologies are in development and have not been approved by the FDA. Safety and efficacy in humans have not been established.